WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Adaptimmune Therapeutics revenue was $178.03M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $3.2M, down 92.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ADAP annual revenue was $178.0M, with 195.3% growth year-over-year.

ADAP past revenue growth

How has ADAP's revenue growth performed historically?

Company
195.34%
Industry
497.69%
Market
20.68%
ADAP's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ADAP's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ADAP's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ADAP revenue history

Current Revenue
$178.0M
Current Earnings
-$70.8M
Current Profit Margin
-39.8%

Be the first to know when ADAP announces revenue.

ADAP Revenue History By Year

ADAP Yearly RevenueADAP RevenueADAP ChangeADAP Revenue Growth
2024-12-31$178.03M$117.75M+195.34%
2023-12-31$60.28M$33.13M+122.05%
2022-12-31$27.15M$21.00M+341.50%
2021-12-31$6.15M$2.19M+55.36%
2020-12-31$3.96M$2.84M+252.76%
2019-12-31$1.12M-$58.38M-98.11%
2018-12-31$59.51M$21.67M+57.28%
2017-12-31$37.83M$23.64M+166.47%
2016-12-31$14.20M$4.33M+43.84%
2015-06-30$9.87M$9.05M+1,096.48%
2014-06-30$825.00kN/AN/A

1 of 1

Adaptimmune Therapeutics Revenue FAQ

What was ADAP's revenue last quarter?

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 2024 revenue of $3.22 million up 1,294.81% year over year. In the same quarter last year, Adaptimmune Therapeutics's revenue was $231.00 thousand.

What was Adaptimmune Therapeutics's revenue in 2024?

Adaptimmune Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $178.03 million, a 195.34% increase year over year.

How much does Adaptimmune Therapeutics make in a day?

Based on Adaptimmune Therapeutics annual revenue for the past five years, ADAP makes an average of $150,996.16 per day.

What was Adaptimmune Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Adaptimmune Therapeutics's revenue has grown 195.34% year over year. This is 302.36 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Adaptimmune Therapeutics's revenue in the past year totaled $178.03 million.

How much does Adaptimmune Therapeutics make in a year?

Adaptimmune Therapeutics's revenue by year for the past five years is:
  • Adaptimmune Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $178.03 million, a 195.34% increase year over year.
  • Adaptimmune Therapeutics's annual revenue for Dec 31, 2023 was $60.28 million, a 122.05% increase from 2022.
  • Adaptimmune Therapeutics's annual revenue for 2022 was $27.15 million, a 341.5% increase from 2021.
  • Adaptimmune Therapeutics's annual revenue for 2021 was $6.15 million, a 55.36% increase from 2020.
  • Adaptimmune Therapeutics's annual revenue for 2020 was $3.96 million, a 252.76% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.